Anti-NMO antibody positive means antibodies against aquaporin‑4 (AQP4‑IgG) are detected in the blood. This supports a diagnosis of neuromyelitis optica spectrum disorder (NMOSD), an autoimmune disease that causes severe optic neuritis and long spinal-cord inflammation. A positive result helps distinguish NMOSD from multiple sclerosis and usually indicates the need for long-term immunosuppressive treatment to prevent relapses.

The NMO and MOG antibody tests detect autoantibodies linked to inflammatory demyelinating conditions of the central nervous system. NMO (AQP4) antibodies target aquaporin‑4 and support diagnosis of neuromyelitis optica spectrum disorder; MOG antibodies target myelin oligodendrocyte glycoprotein and indicate MOG‑associated disease. Both are usually performed on blood (sometimes CSF) by cell‑based assays to distinguish conditions and guide treatment.

The blood test for neuromyelitis optica (NMO) detects aquaporin‑4 IgG (AQP4‑IgG) autoantibodies, usually using a cell‑based assay because it’s the most sensitive and specific method. A positive AQP4‑IgG supports an NMO spectrum disorder diagnosis. If AQP4‑IgG is negative but suspicion remains, clinicians may test for myelin oligodendrocyte glycoprotein IgG (MOG‑IgG).

Neuromyelitis optica (NMO) is a rare autoimmune inflammatory disorder of the central nervous system that primarily targets the optic nerves and spinal cord, causing optic neuritis and transverse myelitis. It often involves antibodies against aquaporin‑4, leads to vision loss, weakness, sensory changes and bladder/bowel dysfunction, and typically follows a relapsing course requiring immunosuppressive treatment to reduce attacks and disability.

No. Neuromyelitis optica (NMO) is a distinct autoimmune disorder, not a form of multiple sclerosis. It primarily affects the optic nerves and spinal cord and is often linked to aquaporin‑4 (or MOG) antibodies. Diagnosis, MRI patterns, and treatments differ from MS; some MS medications can worsen NMO, so accurate diagnosis guides appropriate therapy and prognosis.

Treatment targets acute attacks with high‑dose IV corticosteroids and plasma exchange for steroid‑refractory cases. Long‑term relapse prevention uses immunosuppression: B‑cell depleters (rituximab, inebilizumab), complement inhibition (eculizumab), IL‑6 blockade (tocilizumab, satralizumab), or oral agents (azathioprine, mycophenolate). The goal is to suppress AQP4‑IgG–mediated inflammation, reduce relapses and limit permanent neurological disability. Treatment choice is individualized and monitored.